News & Updates

Dual-target vaccine for flu, COVID-19 compares favourably with standalone comparators

18 Jun 2025 by

The investigational influenza–COVID-19 combination vaccine mRNA-1083 has demonstrated noninferiority to recommended standard-care flu and COVID-19 vaccines, with higher immune responses and an acceptable safety profile in adults at least 50 years of age, according to the results of a phase III trial.

Dual-target vaccine for flu, COVID-19 compares favourably with standalone comparators

18 Jun 2025

RSV-ARI nearly triples mortality risk in new study

18 Jun 2025 by

Acute respiratory infection caused by respiratory syncytial virus (RSV-ARI) nearly triples the risk of death, particularly among individuals with chronic underlying respiratory conditions, as shown in a nationwide cohort study in Denmark.

RSV-ARI nearly triples mortality risk in new study

18 Jun 2025

Mindfulness programme may benefit COVID survivors

17 Jun 2025 by

A mindfulness-based stress reduction (MBSR) programme may improve functional and psychosocial outcomes in patients with long COVID, a study suggests.

Mindfulness programme may benefit COVID survivors

17 Jun 2025

Preconception C. trachomatis seropositivity may up risk of miscarriage

16 Jun 2025

Among women with a history of pregnancy loss, prior exposure to Chlamydia trachomatis poses an increased risk of miscarriage, as reported in a study.

Preconception C. trachomatis seropositivity may up risk of miscarriage

16 Jun 2025

Lifestyle modification resolves MASLD, improves adiposity in more PLHIV than standard care

13 Jun 2025 by

Lifestyle modification induced remission of metabolic dysfunction–associated steatotic liver disease (MASLD) in a higher proportion of people living with HIV (PLHIV) than standard care, according to the first randomized controlled trial (RCT) of its kind conducted by researchers from the Chinese University of Hong Kong (CUHK).

Lifestyle modification resolves MASLD, improves adiposity in more PLHIV than standard care

13 Jun 2025

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

12 Jun 2025

At the Asia Vaccines and Antivirals Summit (AVAS) 2025 held in Bangkok, Thailand, two expert-led sessions provided valuable perspectives on the expanding role of oral antivirals in COVID-19 management. Dr Daniel Griffin, an infectious disease specialist and Clinical Instructor of Medicine at Columbia University, New York, US, focused on protecting high-risk populations through the timely use of antiviral therapy. Complementing this, Professor Ching-Tai Huang of Chang Gung University and Memorial Hospital in Taiwan offered practical guidance on clinical management strategies, including patient risk stratification and therapeutic selection.